Tirzepatide compounding shortage: where the regulatory state stands in 2026

The regulatory landscape for compounded Tirzepatide preparations has been shifting rapidly since the FDA first declared Tirzepatide on its drug-shortage list in late 2022. For compounding-pharmacy buyers planning Tirzepatide procurement in 2026, the operational question is no longer "is compounding allowed" but "under what specific framework does my pharmacy's compounding fit." This briefing summarizes the current state.

The 2022-2024 shortage framework

When the FDA placed Tirzepatide on its drug-shortage list in December 2022 (initially as the type-2-diabetes indication under the Mounjaro brand, later extended after Zepbound's weight-management approval), compounding pharmacies under sections 503A and 503B of the Food, Drug & Cosmetic Act became eligible to compound Tirzepatide preparations. The legal framework is specific: when an approved drug is in shortage, compounders can prepare an "essentially-equivalent" version using bulk drug substance to meet patient demand.

The shortage framework drove substantial commercial volume through compounding-pharmacy channels, bulk Tirzepatide active was widely available, and patient demand consistently exceeded Eli Lilly's manufacturing capacity through most of 2023 and the first three quarters of 2024.

October 2024: removal from the shortage list

In October 2024, the FDA announced that Tirzepatide had been removed from the drug-shortage list, Eli Lilly's manufacturing capacity had caught up to commercial demand and the agency determined the shortage had resolved. Under the standard regulatory framework, removal from the shortage list means compounding-pharmacy access to the active ingredient ends after a transition period.

This produced immediate commercial disruption. Compounding pharmacies that had built substantial Tirzepatide-compounding businesses faced the prospect of losing the regulatory cover that made the activity legal. Several compounding-pharmacy industry groups challenged the FDA's removal decision in court.

Late 2024: court rulings and FDA reconsideration

Following litigation by compounding-pharmacy industry groups, the FDA agreed to reconsider the shortage-list removal and clarified the transition framework. The current operational state, as of 2026, is that:

• Compounding pharmacies operating under 503A (patient-specific compounding) continue to have some ability to compound Tirzepatide under specific clinical-need frameworks, with state-pharmacy-board oversight rather than uniform federal allowance
• 503B outsourcing facilities face stricter restrictions on Tirzepatide compounding without an active shortage declaration
• The bulk Tirzepatide active continues to be available globally for research use and for compounding in jurisdictions outside the US that have different regulatory frameworks
• See our 503A vs 503B guide for the operational differences between the two pathways

The state-by-state variation in 503A enforcement is the practical reality compounding pharmacies navigate. Florida, Texas, Arizona, and several other states have permissive frameworks; California, New York, and the Northeast have more restrictive enforcement; the FDA's federal position continues to evolve.

What this means for procurement teams today

Three practical implications:

1. **Verify your state-board position before procurement**: The compounding-pharmacy industry has fragmented along state lines. The same Tirzepatide preparation that's clearly permissible in Florida may be regulatorily problematic in California. Procurement decisions need to be matched to the specific state's current framework.

1. **Documentation depth matters more, not less**: Even where compounding is permissible, the documentation expectations have risen. Pharmacies need batch-specific COA, sequence verification, LAL endotoxin testing, and stability data, see our [peptide COA buyer's field guide](/insights/reading-a-peptide-coa-buyers-field-guide) for what specifically should appear on the documentation.

1. **The non-Tirzepatide alternatives are commercial-procurement-relevant**: Retatrutide (Phase 3 development, GIP/GLP-1/glucagon tri-agonist) and the dual GLP-1/glucagon class (Mazdutide, Survodutide) are research-grade compounds that share mechanistic territory with Tirzepatide. Several compounding pharmacies are positioning for these as the next-generation alternatives, see our [GLP-1 class comparison](/insights/glp-1-class-comparison-tirzepatide-retatrutide-mazdutide-survodutide) for the full pharmacology.

What's coming in 2026-2027

Several catalysts may further shift the framework:

• FDA Pharmacy Compounding Advisory Committee (PCAC) review (July 2026): Will evaluate seven peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon, but NOT Tirzepatide. The PCAC outcome doesn't directly affect Tirzepatide compounding eligibility, but it signals the broader regulatory direction. See our PCAC briefing.
• Retatrutide approval timeline: Eli Lilly's Phase 3 readouts for Retatrutide are expected in 2026-2027. Approval could shift bulk-active demand from Tirzepatide to Retatrutide for the next generation of compounding workflows.
• State-board harmonization efforts: Several industry groups are working toward more consistent state-level enforcement; whether this produces uniform federal allowance or further fragmentation remains an open question.

Vialdyne's position on Tirzepatide procurement

We supply Tirzepatide bulk active as a research and commercial-grade active ingredient. Our regulatory team reviews each inquiry against the destination market's current framework and provides written advisory on the documentation depth appropriate to the specific use case before pricing. We do not advise on the legality of any specific compounding workflow, that responsibility remains with the buyer's state-pharmacy-board and FDA-compliance counsel, but we provide the documentation depth needed to support whichever framework the buyer is operating under.

For 503A patient-specific compounding under a state-board permissive framework: standard analytical packet plus LAL endotoxin and stability data on the specific lot. For 503B outsourcing-facility use: full cGMP-aligned documentation including supplier audit support. For research use: standard research-grade analytical packet with documented identity. Specify the intended use at quote stage.